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        Human NK cells are CD56    CD3        large granular 
lymphocytes of the innate immune system (  1  ). 
NK cells participate in early responses against 
  infection or malignant transformation through 
production of cytokines and chemokines and via 
direct cytotoxicity in the absence of cognate 
MHC ligands (  2, 3  ). Additionally, NK cells regu-
late the adaptive immune response by interacting 
with DCs and by polarizing CD4     helper T cell 
cytokine production toward a Th1 response ( 4  –  6  ). 
Two functionally distinct subsets of human NK 
cells can be identifi  ed by their surface expression 
of CD56 (  7  ). CD56  dim   NK cells are more abun-
dant in blood than CD56  bright   cells, whereas the 
opposite is true in LNs (  8  ). Functionally, CD56  dim   
NK cells are effi   cient eff  ectors of natural and 
antibody-dependent cytotoxicity, whereas the 
CD56  bright   NK cells produce abundant immuno-
regulatory cytokines and chemokines in response 
to monokine costimulation (  9, 10  ). 
  Monokine-activated NK cells produce pro-
infl  ammatory cytokines required for monocytes/
macrophage clearance of pathogens and eff  ec-
tive tumor surveillance (  11  –  14  ). The prototypic 
cytokine is IFN-    , and it is produced by NK 
cells in response to IL-1, -12, -15, and -18, cy-
tokines for which NK cells express functional 
receptors (  3, 9  ). NK IFN-     in turn promotes 
the maturation and activation of monocytes, 
and is a potent activator of macrophage func-
tions such as antigen presentation and phago-
cytosis (  15  ). The activation of NK cell IFN-     
production is a complex process involving a 
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  Monokines (i.e., interleukin [IL]-12, -18, and -15) induce natural killer (NK) cells to pro-
duce interferon-      (IFN-     ), which is a critical factor for immune surveillance of cancer and 
monocyte clearance of infection. We show that SET, which is a potent inhibitor of protein 
phosphatase type 2A (PP2A) activity, is highly expressed in human CD56  bright   NK cells, 
which produce more IFN-      than CD56  dim   NK cells. SET was up-regulated upon monokine 
stimulation of primary human NK cells. Furthermore, ectopic overexpression of SET signifi  -
cantly enhanced IFN-      gene expression in monokine-stimulated NK cells. In contrast, 
RNAi-mediated suppression of SET expression renders NK cells ineffi  cient in producing high 
levels of IFN-      in response to monokine costimulation. Mechanistically, suppression of 
PP2A activity by SET is important for IFN-      gene expression in NK cells. In fact, treatment 
of primary human NK cells with the PP2A activator 1,9-dideoxy-forskolin, as well as ad-
ministration of the drug to C57BL/6 mice, signifi  cantly reduced NK-dependent IFN-      
production in response to monokine treatment. Further, SET knockdown or pharmacologic 
activation of PP2A diminished extracellular signal-regulated kinase 1/2, p65RelA, signal 
transducer and activator of transduction 4 (STAT4), and STAT5 activity in monokine-
stimulated NK cells, potentially contributing to the reduction in IFN-      gene expression. 
Thus, SET expression is essential for suppressing PP2A phosphatase activity that would 
otherwise limit NK cell antitumoral and/or antiinfl  ammatory functions by impairing NK cell 
production of IFN-     . 2398 SET REGULATES NK CELL IFN-     | Trotta et al.
  Role of SET in the regulation of IFN-      production 
by monokine-stimulated NK cells 
  Based on the observation that IL-12, -15, and -18 monokines 
increase SET levels and that CD56  bright   NK cells express more 
SET protein than CD56  dim   NK cells, we hypothesized that 
SET could be a positive regulator for IFN-     production in 
monokine-costimulated NK cells. Thus, we interfered with 
SET expression by (a) retrovirally infecting the NK-92 cells 
with pSUPER.retro-GFP/neo vector (pSUPER) carrying a 
short hairpin RNA (shRNA) corresponding to nucleotide 
120  –  138 of human SET and GFP (pSUPER.retro-shSET) 
(  21  ); and (b) ectopically expressing an Epstein  –  Barr virus/
retroviral PINCO hybrid vector containing SET and GFP 
multitude of positive and negative mediators, such as kinases 
and phosphatases, as well as transcription factors (  16  –  18  ). 
  The SET (I2PP2A, IGAAD, and TAF1b) protein is local-
ized to the nucleus and cytoplasm and has a critical role in the 
regulation of normal and cancer signal transduction (  19  ). In 
fact, SET is a potent inhibitor of protein phosphatase 2A 
(PP2A) activity (  20, 21  ), even though it has also been de-
scribed as an inhibitor of the tumor suppressor NM23-H1, 
which is a granzyme A DNase-activated factor (  22  ), and a 
negative regulator of histone acetylation (  23  ). PP2A is the 
major cellular serine threonine phosphatase involved in the 
regulation of a variety of cellular processes and signal trans-
duction pathways (  19, 24, 25  ), yet its role in the regulation of 
NK cell biology has not been fully explored. There is some 
evidence that PP2A may be involved in the expansion and 
activation of mouse NK cells in vivo. In fact, the in vivo 
  administration of the PP2A inhibitor cytostatin (CTS) can 
inhibit B16 melanoma pulmonary metastasis, possibly via the 
up-regulation of cytokines that are important for NK cell 
development and/or activation (  26  ). 
  We show that human NK cell subsets diff  erentially ex-
press SET and use it to regulate NK IFN-     gene expression. 
The involvement of SET in the regulation of NK IFN-     
production is strictly dependent on its ability to suppress 
PP2A activity. This also prevents the PP2A-mediated dephos-
phorylation of extracellular signal-regulated kinase (ERK), 
p65RelA, signal transducer and activator of transduction 
(STAT) 4, and STAT5, which are signaling intermediates 
known to be involved in monokine-activated NK cell induc-
tion of IFN-     (  27  –  34  ). 
    RESULTS   
  SET expression in resting and monokine-activated human 
NK cells 
  Stimulation of NK cells with IL-12 and -18 induces a rapid 
increase in the expression of IFN-     (  3, 7, 9  ). Using a gene 
chip screen to assess potential regulatory mechanisms of IFN-     
production in NK cells, we found SET mRNA signifi  cantly 
up-regulated upon costimulation of NK-92 cells (a human 
CD56  bright   NK cell line) (  35  ) with IL-12 and -18 (unpublished 
data). Accordingly, up-regulation of SET mRNA (  Fig. 1 A  , 
left) and protein (  Fig. 1 A  , right) was observed within 6 and 8 h 
of monokine stimulation of NK-92 cells.   Likewise, over-
night costimulation of primary human NK cells with IL-12/
-18  –   or IL-12/-15  –  enhanced SET mRNA (  Fig. 1 B  , left) and 
protein (  Fig. 1 B  , right) expression. Similar eff  ects on induc-
tion of SET expression were noted after single-monokine 
(i.e., IL-12, -15, or -18) stimulation (Fig. S1, available at http://
www.jem.org/cgi/content/full/jem.20070419/DC1). The 
IL-12/-18  –  mediated up-regulation of SET was not altered by 
neutralizing secreted IFN-     (Fig. S2). Interestingly, the rest-
ing CD56  bright   NK cell subset, which has a signifi  cantly en-
hanced capacity to invoke a cytokine response to monokine 
costimulation, constitutively expresses relatively high levels of 
SET protein compared with the more cytolytic CD56  dim   NK 
cell subset (  Fig. 1 C  ). 
  Figure 1.     SET expression in NK cells. (A) NK-92 cells were costimu-
lated with the monokines IL-12 (10 ng/ml) and -18 (100 ng/ml) for the 
indicated times, after which cell pellets were collected and analyzed for 
SET transcript by real-time RT-PCR (*, P      0.03;   n    5; left) and for pro-
tein by Western blot (right). Human CD56   CD3       primary NK cells (B) and 
CD56  bright   and  CD56 dim   primary NK subsets (C) were either unstimulated 
(none) or costimulated with the monokines IL-12 (10 ng/ml) and -18 
(100 ng/ml) and/or -15 (100 ng/ml) for 14 h. Cells were analyzed for SET 
transcript levels by real-time RT-PCR (* and **, P      0.03;   n    6, both condi-
tions; B, left) and for SET protein levels by Western blot (B [right] and C). 
Western blots were performed with anti-SET and -Grb2 antibodies se-
quentially on the same fi  lter. Western blot results are representative of no 
less than three such experiments with virtually identical results. The den-
sitometry analysis of SET protein levels in resting and monokine-activated 
CD56  bright   and  CD56 dim   NK cells are illustrated in C (right), and the graph 
summarizes the data from three different experiments. Error bars in 
A and B represent the SEM of triplicates in one representative experiment, 
and in C the represent the SEM of triplicates in three experiments.     JEM VOL. 204, October 1, 2007 
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PINCO-transduced NK-92 cells, which were both costimu-
lated with the aforementioned monokine combinations (  Fig. 
2 C  ). Similarly, a signifi  cantly higher amount of IFN-     was 
detected in IL-12/-18  –  stimulated CD56    GFP    -sorted pri-
mary human NK cells infected with PINCO-SET compared 
with PINCO-transduced cells (  Fig. 2 D  ). 
  SET up-regulates IFN-      gene expression through 
suppression of PP2A activity 
  To determine whether the monokine-induced and SET-
mediated induction of IFN-     depend on the ability of SET 
to suppress PP2A activity in NK cells, PP2Ac was immuno-
precipitated from lysates of pSUPER.retro-shSET  –   and 
pSUPER-transduced NK-92 cells, and immunoprecipitates 
cDNAs (PINCO-SET) in NK-92 and primary human NK 
cells. In all experiments using these infected cells, sorting was 
fi  rst performed to enrich for the GFP     fraction. 
  As expected, expression of the SET shRNA in the GFP     
NK-92 cell fraction down-regulated SET expression at mRNA 
(not depicted) and protein levels (  Fig. 2 A  , inset) without af-
fecting the expression of pp32 (PP2A inhibitor 1 [I1PP2A]) or 
that of the PP2A catalytic (PP2Ac) subunit (  Fig. 2 A  , inset).   
  Importantly, down-regulation of SET led to a marked 
reduction in IFN-     mRNA expression (  Fig. 2 A  ) and IFN-     
protein (  Fig. 2 B  ) by NK-92 cells in response to costimula-
tion with IL-12/-18, IL-15/-18, and, to a lesser extent, 
IL-12/-15. In contrast, IFN-     production was enhanced in 
GFP     PINCO-SET  –  transduced NK-92 cells compared with 
  Figure 2.     Effect of SET downmodulation and overexpression on IFN-      
production in monokine-stimulated NK cells. (A and B) NK-92 cells were 
retrovirally infected using the pSUPER or pSUPER.retro-shSET vector. Infected 
cells were FACS sorted for GFP and grown in the presence of 0.5 mg/ml 
G418. SET protein levels (A, inset) were analyzed by Western blot. Protein 
lysates were blotted with anti-SET, -I1PP2A, -PP2Ac, and -Grb2 antibodies. 
This experiment is representative of four experiments performed with similar 
results. pSUPER- and pSUPER.retro-shSET  –  infected NK-92 cells were enriched 
by sorting for GFP     cells, stimulated for 18 h with various combinations of 
IL-12 (10 ng/ml), -18 (20 ng/ml), or -15 (100 ng/ml), and then quantifi  ed for 
induction of IFN-     transcript by real-time RT-PCR (left) or secretion of IFN-     
protein by ELISA (*, **, and ***, P      0.004;   n    6, for all conditions, ELISA; 
right). This experiment is representative of six performed with similar results. 
Similar signifi  cant (P      0.009 for all conditions) results were obtained after 
only 4 h of monokine activation (not depicted). NK-92 cells (C) and primary 
NK cells (D) were retrovirally infected using the PINCO or PINCO-SET vector. 
Infected cells were FACS sorted for GFP. SET protein levels were analyzed by 
Western blot (C, inset). Protein lysates were blotted with anti-SET, -Flag, and 
-actin antibodies. GFP     PINCO- and PINCO-SET  –  infected NK-92 (C) and 
primary human NK cells (D) were stimulated for 18 h with IL-12, -18, and/or 
-15 and quantifi  ed for secretion of IFN-     protein by ELISA (C: *, **, and ***, 
P      0.04,   n    4, for all conditions; D: *, P      0.002,   n    4). Error bars repre-
sent the SEM of triplicates in one representative experiment.      
  Figure 3.     Pharmacologic induction of PP2A activity reduces IFN-     
gene expression in monokine-activated NK cells. (A) PP2A phosphatase 
assay was performed using PP2A immunoprecipitates obtained from cellular 
extracts of pSUPER- and pSUPER.retro-shSET  –  infected NK-92 cells (*, P     
0.001;   n    4; left) or primary NK cells treated with the PP2A activator 1,9-
dideoxy-forskolin (**, P      0.001;   n    4; right). NK-92 (B) and primary human 
NK cells (C) were fi  rst incubated (6 or 18 h) with medium containing either 
DMSO vehicle control or 1,9-dideoxy-forskolin, followed by an additional 18 h 
of incubation in the presence of IL-12 (10 ng/ml), -18 (100 ng/ml), and/or 
-15 (100 ng/ml). Cell pellets were then collected for quantifi  cation of IFN-     
transcript by real-time RT-PCR (B and C, left) and supernatants were col-
lected and quantifi  ed for IFN-     protein production by ELISA (B and C: *, **, 
and ***, P      0.008,   n    5, for all conditions as quantifi  ed by ELISA; right). 
This is representative of four experiments performed with similar results. 
Error bars represent the SEM of triplicates in one representative experiment.    2400 SET REGULATES NK CELL IFN-     | Trotta et al.
  To further demonstrate that SET-dependent suppression of 
PP2A activity is a necessary step for the induction of IFN-     by 
monokine-stimulated NK cells, 1,9-dideoxy-forskolin (8 mg/
kg/day; LD  50   = 68 mg/kg) or vehicle (2% DMSO) was admin-
istered i.p. for 3 consecutive days to C57BL/6 mice (  n   = 5 
mice per group). To stimulate in vivo IFN-     production by 
NK cells, IL-12 (1     g/mouse) and -18 (1     g/mouse) were co-
administered i.p. to all mice 5 h after the last injection with 
vehicle or 1,9-dideoxy-forskolin. 18 h after monokine stimula-
tion, vehicle- (DMSO) and 1,9-dideoxyforskolin-treated mice 
were killed, and intracellular staining for IFN-     was performed on 
splenocytes labeled with anti-NK1.1 and CD3 antibody. Con-
sistent with the existence of a functional link between SET ex-
pression, PP2A activity, and IFN-     production in NK cells, gated 
NK1.1    CD3        NK cells from 1,9-dideoxy-forskolin-treated 
mice produce signifi  cantly less IFN-  g   than NK cells from 
DMSO-treated mice (  Fig. 5 B  ).   Similar to the ex vivo experi-
ments with human NK cells, the in vivo administration of 
IL-12 and -18 also induced substantially less IFN-     transcript 
in splenocytes obtained from 1,9-dideoxy-forskolin  –  treated 
mice compared with vehicle-treated mice (  Fig. 5 A  ). Thus, the 
ability of SET to regulate IFN-     gene expression is dependent 
on its inhibitory control of PP2A activity. 
  Evidence for SET as a regulator of additional NK 
cell functions 
  We conducted some additional preliminary experiments to 
determine if SET might have a role in other NK cell functions. 
SET regulation of chemokine MIP-1     gene expression is 
similar to that seen with IFN-    , yet more modest in its ef-
fect (unpublished data). Down-regulation of SET in NK-92 
cells infected with pSUPER.retro-shSET markedly dimin-
ishes their proliferative capacity compared with NK-92 cells 
infected with the pSUPER control (unpublished data). Finally, 
were used in phosphatase assays with PP2A-suitable phospho-
peptide as substrate (  21  ). Downmodulation of SET signifi  -
cantly augmented PP2A catalytic activity in NK-92 cells (  Fig. 
3 A  , left). Additionally, treatment with 1,9-dideoxy-forskolin, 
which is a forskolin derivative that lacks adenylate cyclase-
activating function while retaining the ability to activate PP2A 
(  21, 36  ), effi   ciently induced PP2A activity in primary human 
NK cells (  Fig. 3 A  , right) and NK-92 cells (not depicted).   
Furthermore, PP2A activation by 1,9-dideoxy-forskolin (  Fig. 3, 
B and C  ) and forskolin (not depicted) resulted in decreased 
IFN-     mRNA (left) and secreted protein levels (right) in 
  monokine-activated NK-92 (  Fig. 3 B  ) and primary NK (  Fig. 
3 C  ) cells. PP2A activation by 1,9-dideoxy-forskolin inhibited 
monokine-induced IFN-     production also in NK-92 cells 
ectopically overexpressing SET (  Fig. 4  , left). 
  To further strengthen the functional relationship between 
the SET  –  PP2A interplay and IFN-     production, we pre-
treated (1 h) SET shRNA-expressing (pSUPER.retro-shSET) 
and pSUPER-transduced NK-92 cells with the serine/threo-
nine phosphatase inhibitor okadaic acid (  Fig. 4  , middle) and 
the specifi  c PP2A inhibitor CTS (  Fig. 4  , right) (  37  ) and used 
them to assess changes in the levels of IFN-     secreted by 
IL-12/-18  –  costimulated NK-92 cells.   As expected, both oka-
daic acid and CTS induced IFN-     production in pSUPER.
retro-shSET  –  transduced cells (  Fig. 4  , lane 2, middle and right), 
and also rescued IFN-     production, albeit not completely, in 
pSUPER.retro-shSET  –  expressing cells (  Fig. 4  , lane 4, middle 
and right). 
  Figure 4.     Modulation of PP2A overrides SET-mediated regulation 
of IFN-      production in human NK cells. PINCO and PINCO-SET NK-92 
cells were fi  rst incubated for 24 h at 37  °  C in medium containing DMSO 
vehicle (1 and 3) or 40     M of 1,9-dideoxy-forskolin (2 and 4), and then 
stimulated overnight in the presence of IL-12 plus -18. pSUPER- and 
pSUPER.retro-shSET  –  infected NK-92 cells were treated for 1 h with vehi-
cle (DMSO or water; 1 and 3), 20 nM of the PP2A inhibitor okadaic acid 
(2 and 4), or 2     g/ml of the PP2A inhibitor CTS (2 and 4), followed by 
overnight incubation in IL-12 plus -18. Supernatants were collected and 
assayed for IFN-     protein by ELISA. Results are representative of three 
experiments, and expressed as a percentage of IFN-     increase or decrease 
compared with PINCO- or pSUPER-infected NK-92 cells stimulated with 
IL-12 plus -18 in a fashion identical to experimental wells. The absolute 
value of IFN-     for 0% of the monokine-activated, DMSO-treated, PINCO-
infected NK-92 cells is 61,541 pg/ml (left); the absolute value of IFN-     for 
0% of the monokine-activated, DMSO-treated, pSUPER-infected NK-92 
cells is 430,854 pg/ml (middle); and the absolute value of IFN-     for  0% 
of the monokine-activated, H2O-treated, pSUPER-infected NK-92 cells is 
124,456 pg/ml (right). Error bars represent the SEM of triplicates in one 
representative experiment.     
  Figure 5.     Effect of PP2A activation on IFN-     production in vivo. 
C57BL/6J mice, treated for 3 d with vehicle (DMSO in PBS; 5 mice) or 
1,9-dideoxy-forskolin (8 mg/kg/d; 5 mice), received an IP injection of 1    g 
IL-12 plus 1     g IL-18. After 18 h, spleens were harvested and splenocytes 
were collected for immediate quantifi  cation of IFN-     transcript (*, P     
0.001,   n    5; A) or cultured for 4 h in Brefeldin A, stained with NK1.1-
APC and CD3-FITC antibodies, permeabilized, and stained with an anti  –
 mouse  IFN-   -PE or control isotype-PE mAb (B). The histogram (middle) 
and graph (right) show the results of flow analysis for IFN-     in 
NK1.1   CD3       NK cells from DMSO or 1,9-dideoxy-forskolin  –  treated mice 
as IFN-     inhibition (mean percentage; **, P      0.001;   n    5). Error bars 
represent the SEM of data obtained from fi  ve mice.     JEM VOL. 204, October 1, 2007 
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high levels of SET (  Fig. 1 C  ) have diminished PP2A activity 
(  Fig. 6 C  , left) and increased ERK phosphorylation (  Fig. 6 C  , 
right). In contrast, low SET expression in CD56  dim   NK cells 
(  Fig. 1 C  ) correlated with increased PP2A and decreased ERK 
activity (  Fig. 6 C  , left and right). 
    DISCUSSION   
  NK cells are important components of the innate immune 
system not only because of their ability to mediate cytotoxic-
ity against pathogen-infected or tumor cells but also for their 
ability to produce immunoregulatory molecules, such as che-
mokines and cytokines (  3  ). Specifi  cally, NK cells produce 
IFN-    , whose fundamental role during infl  ammation and 
tumor immunity has been well established. IFN-     defi  ciency 
results in increased susceptibility to infection and/or malig-
nancy (  14, 38  ), whereas overproduction of IFN-     leads to 
autoimmune disorders (  39  ). Hence, a complete understand-
ing of the molecular pathways that regulate IFN-     expression 
is of fundamental importance, and the discovery of new reg-
ulators can help to identify new therapeutic targets for chronic 
infl  ammation and/or cancer. 
  In this study, we identifi  ed SET as a novel positive regula-
tor of IFN-     production by NK cells. In particular, we dis-
covered that SET protein is constitutively abundant in resting 
CD56  bright   NK cells, which are the subpopulation of NK cells 
that produce higher amounts of IFN-    , compared with CD-
56  dim   NK cells (  7  ). We found that potent proinfl  ammatory 
monokines (IL-12, -15, and -18) that stimulate NK cell IFN-     
induced up-regulation of SET mRNA and protein in NK 
cells. We show that SET regulates monokine-inducible IFN-     
production in NK cells via the inhibition of PP2A serine/
threonine phosphatase activity and, further, that down-regu-
lation of SET or enhanced PP2A activity decrease activation 
of signaling molecules associated with the induction of IFN-     
gene expression. Collectively, these data establish that SET 
expression is involved in the regulation of IFN-     expression 
in human NK cells. Notably, to our knowledge, this repre-
sents the fi  rst investigation of the SET-PP2A axis in the hu-
man immune response. Future studies may extend the role of 
SET to other cell types and functions of the immune system. 
  Up-regulation of SET mRNA expression in monokine-
activated primary NK cells directly correlates with the dy-
namics of SET protein expression, suggesting that induction 
and/or stabilization of the SET transcript and protein are 
tightly linked in this instance. The diff  erence in constitutive 
SET expression found in resting CD56  bright   and CD56  dim   NK 
subsets may depend, at least in part, on their distinct micro-
environments. CD56  bright   NK cells develop in the T cell  –   and 
DC-rich parafollicular region of human LNs, where DC-
derived IL-12, -15, and -18 may promote higher SET ex-
pression in this population (  8  ). In contrast, highly cytolytic 
CD56  dim   NK cells predominate in blood where monokine 
levels and cell  –  cell contact are negligible, such that SET ex-
pression is lower in this population. Alternatively, it is con-
ceivable that CD56  dim   NK cells uniquely possess an intrinsic 
signaling program that actively suppresses SET expression. 
down-regulation of SET diminishes NK cytotoxicity (Fig. 
S3 A, available at http://www.jem.org/cgi/content/full/jem
.20070419/DC1), whereas overexpression of SET promotes 
NK cytotoxicity (Fig. S3 B). In addition, the activator of 
PP2A, 1,9-dideoxy-forskolin, inhibits NK cell cytotoxicity 
in NK-92 cells that are overexpressing SET (Fig. S3 B). 
  Downstream signaling events modulated by the 
SET  –  PP2A interplay 
  Because PP2A targets several signaling molecules that report-
edly infl  uence IFN-     gene expression, we investigated whether 
the activity of some of these positive regulators of NK IFN-     
expression (e.g., ERK, NF-  	  B, STAT4, and STAT5) (  27  –  34  ) 
was altered in NK cells upon molecular or pharmacologic 
modulation of the SET  –  PP2A interplay. Western blot analyses 
revealed that downmodulation of the PP2A inhibitor SET 
by shRNA or activation of PP2A by 1,9-dideoxy-forskolin 
treatment  resulted in decreased levels of phosphorylated 
ERK  Thr202/Tyr204  , STAT5  Tyr694  , STAT4  Tyr693  , and NF- 	  B p65  Ser536   
in monokine-stimulated NK-92 cells (  Fig. 6, A and B  ).   In 
contrast, levels of phosphorylated p38  Thr180/Tyr182   in mono-
kine-stimulated NK-92 cells was not diminished in the pres-
ence of 1,9-dideoxy-forskolin (unpublished data), suggesting 
that this eff  ect is not global for all signaling intermediates in-
volved in these monokine activation pathways. As expected, 
CD56  bright   primary human NK cells that constitutively express 
  Figure 6.     Reduction of SET or induction of PP2A results in a dimi-
nution of proinfl  ammatory signaling intermediates involved in NK cell 
IFN-     gene expression. Effect of ectopic SET shRNA expression (and con-
sequent down-regulation of SET; A) or pharmacological activation of PP2A 
(B) on the levels of phospho-STAT5  Tyr694 ,  -STAT4 Tyr693 ,  -ERK Thr202/Tyr204 ,  and 
 – NF- 	 B  p65 Ser536   after costimulation of NK-92 cells with 10 ng/ml IL-12, 
100 ng/ml IL-15, and 100 ng/ml IL-18 for 5 min. (C) PP2A phosphatase assay 
was performed using PP2A immunoprecipitates obtained from cellular 
extracts of unstimulated CD56  bright   and  CD56 dim   primary NK subsets (left). 
CD56  bright   and CD56  dim   NK cells were either unstimulated or costimulated 
with monokines for 5 min, and immunoblotting for phospho-ERK  Thr202/Tyr204  
and actin was performed on the same fi  lter (right). The illustrated data are 
representative of no less than three such experiments with identical results. 
Error bars represent the SEM of triplicates in one representative experiment.    2402 SET REGULATES NK CELL IFN-     | Trotta et al.
As stated, some of these direct and or indirect PP2A targets 
are signaling molecules and/or transcription factors that are 
phosphorylated during monokine activation of NK cells and 
contribute to the induction of IFN-     (  27  –  34  ). 
  Because induction of PP2A activity by either SET down-
regulation or administration of the PP2A activator 1,9-dideoxy-
forskolin resulted in diminished phosphorylation of ERK, 
STAT5, STAT4, and RelA (p65), it is plausible that increased 
PP2A activity limits the induction if IFN-     gene expression 
in part by suppressing ERK, STAT5, STAT4, and/or NF-  	  B 
activation. In contrast, a constitutively elevated basal level of 
SET protein in CD56  bright   NK cells (and, consequently, lower 
PP2A activity) is predictably associated with increased amp-
litude in the phosphorylation/activation of IFN-      –  positive 
regulators (e.g., ERK1/2) after monokine stimulation of this 
subset, compared with CD56  dim   NK cells. Defi  nitive evidence 
for the in vivo relevance of this observation will require ad-
ditional experimentation. 
  Although the mechanism whereby SET interferes specifi  -
cally with PP2A catalytic activity remains unclear, the speci-
fi  city of its inhibitory activity on PP2A is also supported by its 
inability to interfere with the function of phosphatases like 
protein phosphatases 1, 2B, and 2C (  20  ). In addition, the SET 
protein is also subject to serine phosphorylation, and the sig-
nifi  cance of this posttranslational modifi  cation has not been 
established (  44  ). SET has been implicated as an inhibitor of 
granzyme A  –  dependent mitochondrial damage and apoptosis 
(  45  ). SET localizes in part to the nucleus, and has been shown 
to modulate chromatin assembly and gene transcription 
(  44, 46  ). By using a chemical activator and inhibitors of PP2A 
activity, as well as by genetically interfering with SET expression, 
we demonstrate that the eff  ects of SET modulation in NK 
cells can be reversed through the pharmacologic manipulation 
of PP2A activity, suggesting that the infl  uence of SET on 
IFN-     transcription is largely PP2A dependent. However, we 
cannot exclude that, in NK cells, these SET-mediated eff  ects 
are, in part, independent of suppression of PP2A. 
  The current study implicates the SET  –  PP2A interplay in 
the regulation of IFN-     production, but this is likely only 
the fi  rst example of the role of this signal transduction path-
way in NK cell biology. Future studies will explore the pre-
liminary observations mentioned here in regard to the role 
of SET  –  PP2A in other NK functions, including cytotoxic-
ity, proliferation, and survival. Furthermore, the regulation 
of SET  –  PP2A during NK cell development will need to be 
investigated. The potential reciprocal interactions between 
SET  –  PP2A and other signal transduction pathways (AKT, 
ERK, JAK/STAT, and NF-  	  B) should be addressed at a 
mechanistic level. For example, we recently reported that 
PP2A activation leads to the SHP-1  –  dependent inactivation 
and proteasome degradation of leukemogenic oncogenes 
(  21  ). As SET is also overexpressed in various types of cancers 
(  44, 47, 48  ) and induced by cytokines in normal lymphoid 
(unpublished data) and myeloid progenitors (  21  ), it is possible 
that the monokine-induced SET overexpression in NK cells 
might also have a role in the regulation of the NK cell tumor 
  The regulation of IFN-     production by human NK cells, 
as with any process in any cell type, is achieved through the 
integration of dynamic positive and negative signals that refl  ect 
the intrinsic properties of the cell and its external milieu. Whereas 
monokines synergistically induce IFN-     transcription, the 
  immunoregulatory TGF-  
   attenuates IFN-     transcription (  18  ). 
Additionally, NK cells achieve negative feed  back regulation of 
IFN-     production through the monokine-inducible expression 
of the transcription factor Hlx (  40  ). In CD56  bright   NK cells, the 
monokine-induced IFN-     production is also partially depen-
dent on the expression and activity of SHIP1 inositol phos-
phatase. As SHIP1 is responsible for inactivation of AKT, ERK, 
and p38 mitogen-activated protein kinase (MAPK) pathways, 
it is intuitive that both resting and activated CD56  bright   NK 
cells exhibit very low levels of SHIP1 (  17  ). Interestingly, SET 
mRNA and protein levels are lower in NK cells derived from 
SHIP1-null mice than NK cells from wild-type animals (un-
published data). However, whether there is a direct link be-
tween SHIP1 and SET expression in human NK cells remains 
to be investigated. 
  Data from the current study suggest a potential model 
whereby monokines not only directly activate signaling mol-
ecules such as MAP kinases, NF-  	  B, and JAK/STATs, which 
induce IFN-     gene expression in NK cells, but also work via 
the induction of SET to inhibit the activity of PP2A, which 
is a potent and negative regulator of these pathways (  Fig. 7  ).   
PP2A is a heterotrimeric enzyme that consists of a scaff  old 
(A) subunit, a catalytic (C) subunit, and one of a diverse array 
of regulatory (B) subunits (  19  ). The extensive number of dif-
ferent regulatory subunits enables PP2A to act on a wide 
range of signaling substrates (  24  ). In particular, PP2A has 
been shown to modulate the activities of kinases or their sub-
strates, such as ERK MAPKs, JAKs, JNK, PKB, IKB kinases, 
and Rel A, resulting in the regulation of numerous transcrip-
tional factors, such as AP-1, NF-  	  B, and STATs (  21, 24, 41  –  43  ). 
  Figure 7.     A model for the role of SET in regulating IFN-      gene 
expression of NK cells after monokine costimulation. A variety of 
proinfl  ammatory monokines can induce phosphorylation of positive signal-
ing intermediates involved in the induction of IFN-    . In addition, the same 
monokines augment IFN-     gene expression by inducing SET that, in turn, 
interferes with PP2A catalytic activity, which then reduces dephosphoryla-
tion of the proinfl  ammatory signaling intermediates. The resultant direct 
induction of phosphorylation and reduction of dephosphorylation leads to 
optimal IFN-     gene expression after monokine costimulation of NK cells.    JEM VOL. 204, October 1, 2007 
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  Cell culture conditions.     Before monokine stimulation, NK-92 cells were 
cultured in IL-2  –  free medium containing 10% FBS for 36 h. Cells were next 
incubated in medium plus 10% FBS at 37  °  C (10  6  /ml) for the indicated times, 
with the addition of various monokines, such as 10 ng/ml IL-12 (Genetics 
Institute, Inc.), 100 ng/ml IL-18 (R  &  D Systems), and 100 ng/ml IL-15 
(Amgen). Where noted, the PP2A activator 1,9-dideoxy-forskolin or forskolin 
(Sigma-Aldrich) was added at 40     M for 6 or 24 h at 37  °  C before monokine 
stimulation. The PP2A inhibitors (  25, 37  ) okadaic acid (20 nM; Calbiochem) 
and CTS (2     g/ml; Peptides International) or vehicle controls (DMSO or 
water) were added 1 h before stimulation and were present throughout mono-
kine stimulation. The neutralizing anti  –  human IFN-     mAb (R  &  D Systems) 
was used at 5     g/ml. 
  Western blot analysis.     Cells were harvested, washed once with ice-cold 
PBS, and lysed (10  8   cells/ml RIPA buff  er: 0.15 M NaCl, 1% NP-40, 0.1% 
SDS, 50 mM Tris, pH 8.0, supplemented with protease and phosphatase in-
hibitors, 1 mM PMSF, 1 mM Na  3  VO  4  , 50 mM NaF, 10 mM   
  -glycerol-
phosphate, 1 mM EDTA, and a protease inhibitor cocktail tablet from Roche) 
as previously described (  51  ). Alternatively, cells were directly lysed in Laemmli 
buff  er (2      10  5   cells/20     l). Western blotting was performed according to 
previously published protocols (  52  ), and antibody-reactive proteins were de-
tected with horseradish peroxidase  –  labeled sheep anti  –  rabbit,   –  mouse, and/or 
  –  goat Ig sera and enhanced chemiluminescence (ECL; GE Healthcare). Pro-
teins were analyzed in 4  –  15% SDS-PAGE (Bio-Rad Laboratories) using re-
ducing conditions. The mAbs and polyclonal antibodies used were as follows: 
rabbit polyclonal anti-SET (I2PP2A; Globozymes); goat polyclonal anti-SET 
(I2PP2A), -pp32 (I1PP2A), and -actin (Santa Cruz Biotechnology); mono-
clonal anti-PP2Ac, clone 1D6 (Millipore); monoclonal anti-FLAG, clone M2 
(Sigma-Aldrich); polyclonal rabbit sera anti  –  phospho-STAT5  Tyr694  ,   –  phospho-
ERK  Thr202Tyr204  , and   –  phospho-NF-KBp65  Ser536   (Cell Signaling Technology); 
polyclonal rabbit sera anti  –  phospho-STAT4  Tyr693   (Zymed Laboratories); and 
monoclonal anti-GRB2 Antibody (Transduction Laboratories). 
  PP2A phosphatase assay.     PP2A assay was performed using the malachite 
green  –  based PP2A immunoprecipitation phosphatase assay kit (Millipore), 
following the manufacturer  ’  s protocol. In brief, cells were washed with 
0.15 M NaCl and lysate with 1% NP-40, 10 mM Hepes, pH 7.5, 0.15 M 
NaCl, and 10% glycerol, with protease and without phosphatase inhibitor. 
50  –  100     g of proteins were diluted in 50 mM Tris-HCl, pH 7.0, 100     M 
CaCl  2  , and PP2A immunoprecipitations were performed using 4     g of anti-
PP2A antibody and 30     l of protein A  –  agarose beads for sample. Immuno-
precipitations were washed and used in the phosphatase reaction following 
the manufacturer  ’  s protocol. The amount of immunoprecipitated PP2A was 
analyzed by Western blots as an internal control using anti-PP2Ac mAb. 
  IFN-        ELISA assays.     Quantifi  cation of human IFN-     was performed as 
previously described (  9  ) using commercially available mAb pairs (Endogen, 
Inc.). Cell-free supernatants were collected after 18 h of incubation at 37  °  C. 
The detection limit was 10  –  30 pg/ml. Results are shown as the mean of 
triplicate wells      the SEM. 
  Detection of IFN-        production by intracellular fl  ow cytometry in 
monokine-treated mice.     C57BL/6J mice were injected i.p. with 200     g/
mouse of 4% DMSO/PBS or 1,9-dideoxy-forskolin in 4% DMSO/PBS 
daily for 3 d (  21  ). 1     g IL-12 and -18 monokines were injected i.p. 5 h after 
the last injection of PBS or 1,9-dideoxy-forskolin. Spleens were harvested 
from C57BL/6J mice 18 h after IL-12 and -18 injection. Splenocytes were 
either processed immediately for mRNA to quantify IFN-     by real-time 
RT-PCR or cultured ex vivo for 4 h with Brefeldin A, harvested, stained 
with anti-NK1.1 APC and anti-CD3 FITC mAbs (BD Pharmingen), fi  xed, 
and permeabilized using Cytofi  x/Cytoperm reagent (BD Biosciences). Cells 
were then stained with an anti  –  mouse IFN-     PE mAb or isotype control-PE 
mAb (BD Pharmingen). Cells were assessed on a FACSCalibur cytometer 
(BD Biosciences), and analyses were performed using the CellQuest (BD 
Biosciences) software program. 
surveillance activity. Finally, the genetic manipulation of SET 
and PP2A within the mouse NK cell lineage, as well as other 
lymphocyte lineages, will permit investigation of the specifi  c 
roles of the SET  –  PP2A interplay in the physiology and patho-
biology of the immune system. 
    MATERIALS AND METHODS   
  Cells lines and NK cell preparations.     The human IL-2  –  dependent NK 
cell line NK-92 (a gift from H. Klingemann, Rush Cancer Center, Chicago, IL) 
was maintained in culture in RPMI 1640 medium (Invitrogen), supple-
mented with 20% heat-inactivated FBS (Invitrogen), 2 mM   l-  glutamine, 
and 150 IU/ml rhIL-2 (Hoff  man-LaRoche, Inc.). The amphotropic-pack-
aging cell line Phoenix (a gift from G.P. Nolan, Stanford University, Stan-
ford, CA) was maintained in culture in DME (Invitrogen)/10% FBS medium 
and grown for 16  –  18 h to 80% confl  uence before transfection by calcium 
phosphate-DNA precipitation (Profection System; Promega). Human NK 
cells were isolated from peripheral blood leukopacks of healthy individuals 
(American Red Cross, Columbus, OH) by incubation for 30 min with 
RosetteSep NK cell antibody cocktail (StemCell Technologies, Inc.), followed 
by Ficoll-Hypaque density gradient centrifugation and overnight plastic 
adherence to remove the monocyte population. The fresh NK cell pre-
parations were   
  85% CD56    , as determined by direct immunofl  uorescence 
using an anti-CD56 PE-conjugated monoclonal antibody (Immunotech). 
Alternatively, homogeneous NK cell preparations were obtained from 10-d 
cocultures of PBL from healthy individuals admixed with irradiated (30 Gy) 
RPMI 8866 cells (  49  ). NK cell preparations containing   
  98% CD56     NK 
cells were obtained by positive selection using CD56 MicroBeads and 
MACS Separation Columns (Miltenyi Biotech). CD56  bright   and CD56  dim   
NK cell subsets were purifi  ed from fresh blood based on CD56 cell-surface 
density by FACS upon staining with the anti  –  CD56-PE antibody (  17  ). All 
work with human materials was approved by the Institutional Review Board 
of The Ohio State University Comprehensive Cancer Center. 
  Retroviral infection of the NK-92 cell line and primary human NK 
cells.     The generation of pSUPER.retro-shSET retroviral vector was previ-
ously described (  21  ), as was the GFP-expressing Epstein  –  Barr virus/retroviral 
PINCO hybrid vector for human NK cell infection (  17, 50  ). In brief, the 
shRNA SET constructs were obtained by subcloning the double-stranded 
64-mer oligonucleotide containing the SET target sequence (5   -TGAAATAGA-
CAGACTTAAT-3    ) into the pSUPER.retro.neoGFP vector (pSUPER; 
OligoEngine, Inc.). To generate PINCO-SET, the human SET cDNA was 
obtained from MigRI-FLAG SET (  21  ) by PCR, using a 5     primer contain-
ing the BamHI restriction site, the ATG codon, and the nucleotides encod-
ing for the FLAG epitope, and a downstream primer that includes the last 
nucleotides of SET cDNA linked to an EcoRI restriction site. After BamHI  –
  EcoRI digestion, the FLAG SET product was cloned directionally in the 
BamHI  –  EcoRI-digested PINCO (  17, 50  ). For infection, the NK-92 cell 
line and primary NK cells were fi  rst incubated for 2  –  3 d in the presence of 
900 IU/ml IL-2, and then previously published standards (  51  ) were fol-
lowed. In brief, infectious supernatant from pSUPER, pSUPER.retro-
shSET, PINCO, and PINCO-SET retrovirally transfected Phoenix cells 
were collected after 48 h and used for three cycles of infections. Upon infec-
tion, NK-92 cells were sorted (FACSVantage; BD Biosciences) for GFP 
expression, and primary NK cells were sorted for GFP and CD56 expression 
upon staining with an anti-CD56 allophycocyanin (APC)-conjugated mono-
clonal antibody (Immunotech). GFP    CD56     primary NK cells were used 
for experimentation immediately after sorting. Expression of SET mRNA 
and protein was confi  rmed in NK-92 cells by real-time RT-PCR and 
Western blot. 
  Mice.     C57BL/6J mice, which were obtained from The Jackson Laboratory, 
were 6  –  8-wk-old female littermates. All animal work was approved by The 
Ohio State University Animal Care and Use Committee, and mice were 
treated in accordance with the institutional guidelines for animal care. 2404 SET REGULATES NK CELL IFN-     | Trotta et al.
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  Real-time RT-PCR.     Total mRNA was extracted using RNeasy Mini kits 
(Qiagen) and cDNA was generated according to the manufacturer  ’  s recom-
mendations (Invitrogen). Real-time RT-PCR reactions for IFN-    transcripts 
were performed as a multiplex reaction with a primer/probe set specifi  c 
for the human IFN-     mRNA, as previously described (  17  ). cDNA from 
PHA-activated human lymphocytes served as positive controls for cytokine 
transcripts, and water (no template) was used as a negative control. The human 
SET primers and probe used are as follows: forward primer 5    -AAAAGGAGCT-
CAGAAAAAGAACAGCA-3    , reverse primer 5    -CATCAATGTGTTCAA-
TCGCT-3    , and probe 5    -CCGACGAGACCTCAGAAAAA  GAACACA-3    . 
cDNA samples were used as a template in a PCR-amplifi  cation reaction con-
taining a set of primers and a FAM-labeled probe for the SET transcripts (  1  ), or 
a set of primers and a VIC-labeled probe for 18S (  2  ). Reactions were performed 
using an ABI prism 7700 sequence detector (Taqman; Applied Biosystems), 
and data were analyzed with the Sequence Detector version 1.6 software to 
establish the PCR cycle at which the fl  uorescence exceeded a set threshold, C  T , 
for each sample. Data were analyzed according to the comparative C  T   method, 
as previously described (  3  ), using the internal control 18S transcript levels to 
normalize diff  erences in sample loading and preparation. Results represent the 
  n  -fold diff  erence of transcript levels in a particular sample compared with cali-
brator cDNA (cDNA samples of unstimulated PINCO-infected, pSUPER.
retro  –  infected, or NK-92 cells). Results are expressed as the mean      the SEM 
of triplicate reaction wells. 
  Cytotoxicity assays.     Before the assay, NK-92 eff  ectors cells were cultured 
in IL-2  –  free medium containing 10% FBS for 36 h. K562 were used as target 
in a 3-h   51  Cr release assay (  31  ). A constant number of target cells (10  4   cells/
well) and serial dilution of eff  ectors cells were used in triplicates. Spontane-
ous release was always     10%. 
  Statistics.     For each statistical comparison, a one-sample   t   test was performed. 
Each data point for the experiment under consideration was generated from 
a process that involved a comparison to a control condition. That is, each 
control group value is normalized to 1, and the experimental treatment re-
sulted in a data point that was either      or   
  1. If necessary for the assumption 
of normality, the data were natural log transformed. A one-sample   t   test was 
performed with the      set to 0.05. 
  Online supplemental material.     Fig. S1 shows that single-monokine (IL-12, 
-15, or -18) stimulation of primary NK cells induces SET expression. Fig. S2 
shows that, in primary NK cells, the IL-12/-18  –  induced up-regulation of SET 
is not altered by neutralizing IFN-    . Fig. S3 shows that downmodulation of SET 
diminishes NK cell cytotoxicity, whereas its overexpression promotes NK cell 
cytotoxicity, and that pharmacological activation of PP2A inhibits NK cell cyto-
toxicity in SET-overexpressing cells. The online version of this article is available 
at http://www.jem.org/cgi/content/full/jem.20070419/DC1. 
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